BACKGROUND: Mitochondrial dysfunction has been associated with both human immunodeficiency virus (HIV) infection and exposure to antiretroviral therapy. Mitochondrial dysfunction has not been widely studied in HIV-infected children. We estimated the incidence of clinically defined mitochondrial dysfunction among children with perinatal HIV infection. METHODS: Children with perinatal HIV infection enrolled in a prospective cohort study (Pediatric AIDS Clinical Trials Group protocols 219 and 219C) from 1993 through 2004 were included. Two clinical case definitions of mitochondrial dysfunction, the Enquête Périnatale Française criteria and the Mitochondrial Disease Classification criteria, were used to classify signs and symptoms that were consistent with possible mitochondrial dysfunction. Adjusted odds ratios of the associations between single and dual nucleoside reverse-transcriptase inhibitor use and possible mitochondrial dysfunction were estimated using logistic regression. RESULTS: Overall, 982 (33.5%) of 2931 children met 1 or both case definitions of possible mitochondrial dysfunction. Mortality was highest among the 96 children who met both case definitions (20%). After adjusting for confounders, there was a higher risk of possible mitochondrial dysfunction among children who received stavudine regardless of exposure to other medications (odds ratio, 3.44 [95% confidence interval, 1.91-6.20]) or who received stavudine-didanosine combination therapy (odds ratio, 2.23 [95% confidence interval, 1.19-4.21]). Exposure to lamivudine and to lamivudine-stavudine were also associated with an increased risk of mitochondrial dysfunction. CONCLUSIONS: Receipt of nucleoside reverse-transcriptase inhibitors, especially stavudine and lamivudine, was associated with possible mitochondrial dysfunction in children with perinatal HIV infection. Further studies are warranted to elucidate potential mechanisms of nucleoside reverse-transcriptase inhibitor toxicities.
BACKGROUND:Mitochondrial dysfunction has been associated with both humanimmunodeficiency virus (HIV) infection and exposure to antiretroviral therapy. Mitochondrial dysfunction has not been widely studied in HIV-infectedchildren. We estimated the incidence of clinically defined mitochondrial dysfunction among children with perinatal HIV infection. METHODS:Children with perinatal HIV infection enrolled in a prospective cohort study (Pediatric AIDS Clinical Trials Group protocols 219 and 219C) from 1993 through 2004 were included. Two clinical case definitions of mitochondrial dysfunction, the Enquête Périnatale Française criteria and the Mitochondrial Disease Classification criteria, were used to classify signs and symptoms that were consistent with possible mitochondrial dysfunction. Adjusted odds ratios of the associations between single and dual nucleoside reverse-transcriptase inhibitor use and possible mitochondrial dysfunction were estimated using logistic regression. RESULTS: Overall, 982 (33.5%) of 2931 children met 1 or both case definitions of possible mitochondrial dysfunction. Mortality was highest among the 96 children who met both case definitions (20%). After adjusting for confounders, there was a higher risk of possible mitochondrial dysfunction among children who received stavudine regardless of exposure to other medications (odds ratio, 3.44 [95% confidence interval, 1.91-6.20]) or who received stavudine-didanosine combination therapy (odds ratio, 2.23 [95% confidence interval, 1.19-4.21]). Exposure to lamivudine and to lamivudine-stavudine were also associated with an increased risk of mitochondrial dysfunction. CONCLUSIONS: Receipt of nucleoside reverse-transcriptase inhibitors, especially stavudine and lamivudine, was associated with possible mitochondrial dysfunction in children with perinatal HIV infection. Further studies are warranted to elucidate potential mechanisms of nucleoside reverse-transcriptase inhibitor toxicities.
Authors: Catherine L Cherry; David Nolan; Ian R James; Elizabeth J McKinnon; Simon A Mallal; Michelle E Gahan; Luxshimi Lal; Justin C McArthur; Steven L Wesselingh Journal: J Acquir Immune Defic Syndr Date: 2006-08-01 Impact factor: 3.731
Authors: Grace A McComsey; Minhee Kang; Allison C Ross; Dirk Lebrecht; Elizabeth Livingston; Ann Melvin; Jane Hitti; Susan E Cohn; Ulrich A Walker Journal: HIV Clin Trials Date: 2008 Mar-Apr
Authors: Fernando Scaglia; Jeffrey A Towbin; William J Craigen; John W Belmont; E O'Brian Smith; Stephen R Neish; Stephanie M Ware; Jill V Hunter; Susan D Fernbach; Georgirene D Vladutiu; Lee-Jun C Wong; Hannes Vogel Journal: Pediatrics Date: 2004-10 Impact factor: 7.124
Authors: J Tyler Lonergan; Grace A McComsey; Robin L Fisher; Peter Shalit; Thomas M File; Douglas J Ward; Vanessa C Williams; Siegrid M Hessenthaler; Laura Lindsey; Jaime E Hernandez Journal: J Acquir Immune Defic Syndr Date: 2004-08-01 Impact factor: 3.731
Authors: Sònia López; Oscar Miró; Esteban Martínez; Enric Pedrol; Benjamín Rodríguez-Santiago; Ana Milinkovic; Anna Soler; Miguel A García-Viejo; Virginia Nunes; Jordi Casademont; Josep M Gatell; Francesc Cardellach Journal: Antivir Ther Date: 2004-02
Authors: Steven E Lipshultz; Paige L Williams; Bret Zeldow; James D Wilkinson; Kenneth C Rich; Russell B van Dyke; George R Seage; Laurie B Dooley; Jonathan R Kaltman; George K Siberry; Lynne M Mofenson; William T Shearer; Steven D Colan Journal: AIDS Date: 2015-01-02 Impact factor: 4.177
Authors: Ayotunde James Fasunla; Babatunde Oluwatosin Ogunbosi; Georgina Njideka Odaibo; Onyekwere George Benjamin Nwaorgu; Babafemi Taiwo; David Olufemi Olaleye; Kikelomo Osinusi; Robert Leo Murphy; Isaac Folorunso Adewole; Olusegun Olusina Akinyinka Journal: AIDS Date: 2014-09-24 Impact factor: 4.177
Authors: Gabriel Somarriba; Gabriela Lopez-Mitnik; David A Ludwig; Daniela Neri; Natasha Schaefer; Steven E Lipshultz; Gwendolyn B Scott; Tracie L Miller Journal: AIDS Res Hum Retroviruses Date: 2012-07-31 Impact factor: 2.205
Authors: Luminita Ene; Donald R Franklin; Ruxandra Burlacu; Anca E Luca; Andreea G Blaglosov; Ronald J Ellis; Terry J Alexander; Anya Umlauf; Igor Grant; Dan C Duiculescu; Cristian L Achim; Thomas D Marcotte Journal: J Neurovirol Date: 2014-09-04 Impact factor: 2.643
Authors: Tanvi S Sharma; Denise L Jacobson; Lynn Anderson; Mariana Gerschenson; Russell B Van Dyke; Elizabeth J McFarland; Tracie L Miller Journal: AIDS Res Hum Retroviruses Date: 2013-09 Impact factor: 2.205
Authors: Greg S Gojanovich; Denise L Jacobson; Jennifer Jao; Jonathan S Russell; Russell B Van Dyke; Daniel E Libutti; Tanvi S Sharma; Mitchell E Geffner; Mariana Gerschenson Journal: AIDS Res Hum Retroviruses Date: 2020-07-20 Impact factor: 2.205
Authors: Peter Torre; Bret Zeldow; Howard J Hoffman; Ashley Buchanan; George K Siberry; Mabel Rice; Patricia A Sirois; Paige L Williams Journal: Pediatr Infect Dis J Date: 2012-08 Impact factor: 2.129